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Capecitabine plus oxaliplatin every 3 weeks (XELOX regimen) has proven efficacy in patients with colorectal carcinoma. We
investigated this combination in patients with previously untreated advanced gastric carcinoma. The study population comprised
patients with histologically confirmed nonresectable advanced gastric adenocarcinoma. Patients received intravenous oxaliplatin
130mgm
 2 over 2h on day 1 plus oral capecitabine 1000mgm
 2 twice daily on days 1–14, every 3 weeks. Patients received a
maximum of eight cycles. Twenty evaluable patients (17 men, 3 women) with a median age of 64 years (range 38–75) were enrolled.
The overall response rate was 65% (95% confidence interval (CI), 44–86%), with complete responses in two patients and partial
responses in 11 patients. Median progression-free survival was 7.5 months (95% CI, 3.2–11.7 months); median overall survival was
not reached during the study period. There was no grade 4 and little grade 3 toxicity. The most common haematological adverse
event was anaemia (65% of patients) and the most common nonhaematological toxicities were vomiting (65%), neuropathy (60%),
diarrhoea (30%), and hand–foot syndrome (20%). In conclusion, XELOX is apparently as effective as triplet combinations and is well
tolerated as first-line therapy for advanced gastric carcinoma. We are starting a large multi-institutional phase II study of XELOX in
this setting.
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Gastric cancer remains one of the most common malignancies
worldwide (Parkin et al, 1999), and is the leading cause of cancer-
related deaths in Korea (National Statistical Office, 2001). Despite
improvements in the early diagnosis of gastric cancer, many
patients present with inoperable disease. Advanced gastric
carcinoma remains incurable with a median survival of only 6–
10 months even in patients treated with chemotherapy (Hong et al,
2004; Park et al, 2004; Thuss-Patience et al, 2005).
5-FU in combination with cisplatin (FP regimen) is commonly
used in advanced disease because of the activity of both drugs
when administered as single agents. In randomised phase III trials
in advanced gastric cancer, FP led to improved response rates
compared with 5-FU, doxorubicin and mitomycin (FAM) or 5-FU
single-agent therapy (Kim et al, 1993), and showed a trend towards
improved response rates compared with 5-FU, doxorubicin and
methotrexate (FAMTX) or etoposide, leucovorin and bolus 5-FU
(ELF) (Vanhoefer et al, 2000). Some European centres consider
epirubicin, cisplatin and 5-FU (ECF) to be standard therapy based
on its response and survival advantage over FAMTX (Waters et al,
1999). However, all of these 5-FU-based regimens are inconvenient
to administer and have the potential for severe toxicity (i.e. renal
toxicity, emesis). Therefore, more effective and better-tolerated
systemic therapy is needed to improve the management of patients
with advanced gastric cancer.
The oral fluoropyrimidine capecitabine (Xeloda
s; F Hoffmann
La-Roche) has been designed to generate 5-FU preferentially in
tumours through exploitation of the significantly higher levels of
thymidine phosphorylase in tumour tissue compared with healthy
tissue (Ishitsuka et al, 1998; Schu ¨ller et al, 2000; Miwa et al, 2001).
Capecitabine has shown superior response rates and relapse-free
survival and superior safety compared with i.v. 5-FU/LV in the
treatment of metastatic (Cassidy et al, 2002; Van Cutsem et al,
2004) and adjuvant colorectal cancer (Scheithauer et al, 2003a;
Twelves et al, 2005). Capecitabine 1250mgm
 2 twice daily on days
1–14 every 3 weeks has also been shown to be active (overall
response rate 28%; stable disease 36%) and well tolerated in a
phase II study of previously untreated patients with advanced
gastric cancer (Hong et al, 2004). A 4-weekly intermittent schedule
of capecitabine (828mgm
 2 twice daily for 3 weeks followed by 1
week of rest) also produced overall response rates of 19 and 26% in
two Japanese studies in patients with advanced gastric cancer, with
a median survival of approximately 8.8 months at the time of
reporting (Koizumi et al, 2003; Kondo et al, 2003).
Oxaliplatin, a chemotherapeutic agent currently being investi-
gated in the treatment of gastrointestinal carcinomas (Hoff and
Fuchs, 2003), has a more favourable tolerability profile than
cisplatin and may therefore become an important alternative agent
in this setting. In particular, oxaliplatin is not associated with the
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srenal toxicity commonly seen with cisplatin. The combination of
5-FU with folinic acid and oxaliplatin has been investigated in
a number of different regimens (FOLFOX, FOLFOX4, FOLFOX6,
and FUFOX) in phase II clinical trials and has been shown to be
effective in patients with advanced or metastatic gastric cancer,
achieving overall response rates of 38–56%, median overall
survival of 8.6–11.4 months, and median time to progression of
5.2–7.1 months (Louvet et al, 2002; Al-Batran et al, 2004; Chao
et al, 2004; de Vita et al, 2005; Lordick et al, 2005). Capecitabine
plus oxaliplatin either on a 3-weekly or weekly basis (XELOX and
CAPOX regimens) has demonstrated similar activity to 5-FU-based
combinations as first-line treatment for metastatic colorectal
cancer (Borner et al, 2002; Scheithauer et al, 2003b; Zeuli et al,
2003; Cassidy et al, 2004). In addition, the combination of
capecitabine and oxaliplatin is also being investigated in a phase
III trial (REAL 2) in triplet combinations for the first-line
treatment of gastro-oesophageal carcinoma (Sumpter et al, 2004;
Tebbutt et al, 2004).
The purpose of the present pilot phase II study was to
investigate the efficacy and safety of XELOX combination therapy
in patients with previously untreated advanced gastric cancer.
MATERIALS AND METHODS
Patients
Eligible patients had histologically confirmed advanced or meta-
static gastric adenocarcinoma with unidimensionally measurable
disease. This was defined as at least one tumour lesion measuring
X1.5 1.5cm
2 with clearly defined margins on spiral CT scan,
MRI, or abdominal ultrasound. For patients with proximal lesions,
only those with cardia cancer were eligible, patients with GI
junction tumours (AGE I) were not eligible according to the
classification by Siewert et al (von Rahden et al, 2005). Patients
were X18 years of age with an Eastern Cooperative Oncology
Group (ECOG) performance status of 0–2, and had received no
prior chemotherapy for metastatic disease. Adequate haematolo-
gical (absolute neutrophil count 41500/ml, platelets 4100000/ml),
hepatic (total bilirubin o1.5mgdl
 1, transaminase levels o3 times
the upper normal limit (UNL) or o5 times the UNL in cases of
hepatic metastases), and renal (creatinine o1.5mgdl
 1) function
was required. The protocol was approved by the institutional
review board of the Korean Institute of Radiological and Medical
Science, and all patients gave written informed consent before
enrolment.
Treatment schedule
Oxaliplatin 130mgm
 2 was administered as a 2-h intravenous
infusion on the first day of each 3-week cycle. Capecitabine
was administered orally at a dosage of 1000mgm
 2 twice daily
according to the standard intermittent schedule (from the evening
of day 1 until the morning of day 15 followed by a 7-day rest
period).
Patients received at least two courses of XELOX unless rapid
disease progression occurred after the first or second cycle.
Patients who responded or who had stable disease received
treatment for up to a maximum of eight cycles or until disease
progression occurred.
Dose modification for adverse events
Toxicity was graded according to the National Cancer Institute
(NCI) Common Toxicity Criteria (CTC), Version 2.0 (NCI, 1999).
Dose modifications for isolated abnormal haematological labora-
tory values were based on haematological parameters at the start of
a treatment cycle. There was no scheduled sampling during a
treatment cycle, so there was no scheduled collection of nadir
values.
Capecitabine treatment interruption or dose reduction was not
indicated for grade 1 toxicity or for events unlikely to become
serious or life threatening. Treatment was interrupted in cases of
grade 2 or higher events (with the exception of alopecia, nausea or
vomiting, and anaemia) and was not resumed until the adverse
event resolved or improved to grade 1 or 0. Capecitabine dose
reduction was not required at the first occurrence of a grade 2
event. The capecitabine dose was reduced by 25% to 750mgm
 2
twice daily for patients who experienced a second occurrence of a
given grade 2 event or any grade 3 event.
Capecitabine doses were reduced by 50% to 500mgm
 2 twice
daily for patients who experienced a third occurrence of a given
grade 2 event, a second occurrence of a given grade 3 event, or any
grade 4 event. Treatment was discontinued if, despite dose
reduction, a given adverse event occurred for a fourth time at
grade 2, a third time at grade 3, or a second time at grade 4. If an
adverse event did not improve to grade 1 or less after 3 weeks, the
affected patient was withdrawn from the study.
Oxaliplatin treatment was interrupted in cases of grade 2 or
higher adverse events and was not resumed until the toxicity
resolved or improved to grade 1 or 0. Treatment was discontinued
in cases of grade 3/4 neuropathy. If paresthesiae with pain or with
persistent functional impairment were the only toxicities present
at the time of the next planned administration of oxaliplatin,
oxaliplatin was delayed and capecitabine continued as mono-
therapy. If the neurological toxicity was still present at the time of
the next planned treatment cycle, oxaliplatin was discontinued
permanently. In these circumstances, capecitabine was continued
as monotherapy at the discretion of the investigator.
Evaluation criteria
The primary study end point was the overall response rate as
measured by the number of complete and partial responses.
Secondary end points included progression-free survival (PFS),
overall survival, and safety. A physical examination, including a
neurological examination and complete blood counts, was
performed before the first treatment cycle. Pretreatment evaluation
also included biochemical analyses, chest X-ray, and CT scans to
define the extent of the disease. Complete blood cell counts with
differential and serum biochemistry analyses were repeated at each
treatment cycle. Response was assessed radiologically every two
cycles or when progression was suspected. Evaluations were
performed by physical examination, chest X-ray, abdominal-pelvic
CT scan, or ultrasonography. Complete response, partial response,
stable disease, and progressive disease were defined according to
RECIST criteria (Therasse et al, 2000). All the objective responses
were confirmed after 4 weeks and clinical complete responses were
confirmed as pathological complete responses by gastroendoscopy
biopsy. CT scans were conducted to confirm the responses.
Statistical analysis
The trial was designed using ) testing procedure. Assuming a true
increase in response rate of X10%, 22 patients were to be
included, with a target minimum response of 30% and a maximum
width of 36% for the 95% confidence interval (CI). Overall
response rate (with 95% CI) was calculated for all patients
according to an intention-to-treat analysis. Progression-free
survival was calculated from the first day of chemotherapy until
the date of disease progression. Overall survival was calculated
from the start of study treatment until death. Progression-free
survival and overall survival curves were generated using the
Kaplan–Meier method. Response duration was calculated from
the date of response confirmation to the date of disease
progression.
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sRESULTS
Patient characteristics
Because an ongoing phase II multicentre trial of the same regimen
in an identical patient population was started before this trial was
completed, only 20 of the planned 22 patients were enrolled
(between December 2003 and August 2004). Baseline patient
characteristics are listed in Table 1. Of the 20 patients included, 19
were evaluable for safety and tumour response. The one not
evaluable patient was dropped out after two cycles of chemother-
apy. The median age of the patients was 64 (range 38–75) years,
and most patients (90%) had a good performance status (ECOG 1).
Fifteen patients (75%) had multiple metastases involving two or
more organ systems. The most common metastatic site was the
liver (70%). Median follow-up duration was 11.1 months (range
8.2–14.5). Three patients (16%) had diffuse-type tumours by
Lauren’s classification.
Efficacy
The overall response rate was 65% (95% CI, 44–86%, Table 2).
Two patients (10%) achieved a complete response confirmed
by gastroscopic biopsy. Eleven (55%) partial responses were
observed. The median duration of response in the 13 responding
patients was 10.0 months (range 6.8–13.0 months). One patient
had disease stabilisation, and five (25%) progressed while on
treatment. The median PFS was 7.5 months (95% CI, 3.2–11.7
months) (Figure 1). The median overall survival was not reached at
the time of reporting of this trial.
Safety
A total of 97 treatment cycles (median 6, range 1–8 cycles) were
administered. Haematological and nonhaematological adverse
events associated with treatment are listed in Table 3. No grade
4 toxicity was observed. Grade 1 or 2 anaemia (65%) was the most
common haematological event. Other grade 1 or 2 haematological
events (leucopenia, neutropenia, and thrombocytopenia) were less
common, and affected o40% of patients (Table 3). The only grade
3 events were leucopenia (5% of patients) and neutropenia (5% of
patients).
The most common nonhaematological toxicities were neuro-
pathy and vomiting, each of which affected X60% of patients. The
only grade 3 events observed were vomiting and diarrhoea, which
affected 5% of patients each. These toxicities were invariably mild
to moderate in severity (Table 3). Other nonhaematological
toxicities were diarrhoea, hand–foot syndrome, and stomatitis.
Treatment delays or dose reductions were necessary in 30 of 97
(31%) cycles. Doses were reduced in 17 cycles (18%) as a result of
neutropenia and thrombocytopenia. Treatment was delayed in 13
Table 1 Patient characteristics (n¼20)
Characteristic Number of patients (%)
Age (years)
Median 64
Range 38–75
Sex
Male 17 (85)
Female 3 (15)
ECOG performance status
1 18 (90)
2 2 (10)
Metastatic site
a
Liver 14 (70)
Lung 2 (10)
Abdominal lymph node 11 (55)
Soft tissue 1 (5)
Number of metastatic sites
1 5 (25)
2 9 (45)
X3 6 (30)
aPatients could have more than one metastatic site.
Table 2 Response to treatment (n¼20)
Response No. of patients (%)
Confirmed response 13 (65)
Complete response 2 (10)
Partial response 11 (55)
Stable disease 1 (5)
Progressive disease 5 (25)
Not assessable 1 (5)
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Figure 1 Progression-free survival (n¼20).
Table 3 Haematological and nonhaematological adverse events (n¼20)
Grade (% of patients)
1 234
Anaemia 60 5 0 0
Leukopenia 30 10 5 0
Neutropenia 20 10 5 0
Thrombocytopenia 10 15 0 0
Vomiting 45 15 5 0
Stomatitis 10 5 0 0
Diarrhoea 15 10 5 0
Hand–foot syndrome 15 5 0 —
Neuropathy 55 5 0 0
Oxaliplatin plus capecitabine for advanced gastric cancer
YH Park et al
961
British Journal of Cancer (2006) 94(7), 959–963 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
scycles (13%). The median dose intensities of both drugs exceeded
95%.
DISCUSSION
Capecitabine-based combination chemotherapy for advanced
gastric cancer has been shown to be active in first- and second-
line treatment, achieving response rates in the range of 20–55%
(Koizumi et al, 2003; Hong et al, 2004). Previous large phase III
studies comparing capecitabine with bolus 5-FU plus leucovorin as
first-line therapy for metastatic colorectal cancer have demon-
strated superior response rates, comparable PFS and overall
survival, and a favourable safety profile of capecitabine compared
with 5-FU in this common gastrointestinal cancer (Twelves et al,
2005).
While intravenous 5-FU plus cisplatin has been widely used for
the treatment of advanced gastric cancer with encouraging results,
the regimen is inconvenient for patients due to the continuous
5-FU infusion and is associated with poor tolerability due to the
renal toxicity and severe emesis that can occur with cisplatin.
Oxaliplatin is an important chemotherapeutic agent that is being
investigated in the treatment of gastrointestinal carcinomas (Hoff
et al, 2001). It is likely to become widely used as an alternative
to cisplatin if it achieves more favourable clinical outcomes.
Oxaliplatin is particularly useful in advanced gastric cancer
because of its good toxicity profile.
Our study shows that the XELOX regimen achieved a very good
response rate and PFS in patients with advanced gastric cancer.
Two patients achieved a complete response and a further 55%
achieved a partial response, giving an overall response rate of 65%.
The median PFS was 7.5 months (95% CI, 3.2–11.7 months). This
result is particularly notable given that our patient population was
relatively old with median age of 64 years. Considering that our
measurable disease was defined as at least one tumour lesion
measuring X1.5 1.5cm
2 with clearly defined margins on spiral
CT scan, MRI, or abdominal ultrasound, the objective response
rate of our study could be stricter than others. According to the
RECIST criteria, measurable lesions can be accurately measured in
at least one dimension with the longest diameter X20mm using
conventional techniques or X10mm with spiral CT scan. While
the usual limitations of cross-study comparisons should be taken
into account, these findings compare favourably with two recent
studies investigating the efficacy of cisplatin in combination with
capecitabine as first-line therapy in patients with advanced gastric
cancer, which reported overall response rates of 46 and 55%,
respectively (Kim et al, 2002; Jin et al, 2005). Median time to
progression reported in one study was 6.3 months (Kim et al,
2002).
XELOX also had a good safety profile. No grade 4 toxicity was
reported and grade 3 haematological and nonhaematological
events were rare (o5% of cycles/patients). The most common
toxicities reported were vomiting, neuropathy, and diarrhoea,
which were generally of mild to moderate intensity. The toxicity
profile reported with XELOX in our trial compares favourably with
that of cisplatin–capecitabine as reported by Kim et al (2002), who
observed grade 3/4 neutropenia in 33% of patients (vs 5% of
patients in the present trial). The rate of grade 2 peripheral
neuropathy in our study may be considered somewhat low. In a
study of oesophageal cancer, Mauer et al (2005) reported a rate of
26% for grade 2/3 peripheral neuropathy.
A large ongoing phase III trial (REAL 2) is currently
investigating replacing 5-FU with capecitabine and cisplatin with
oxaliplatin in triplet combinations with epirubicin for the first-line
treatment of gastro-oesophageal carcinoma (Sumpter et al, 2004;
Tebbutt et al, 2004). Early indications from the REAL 2 study
indicate that the combination of capecitabine and cisplatin could
be effective in triplet therapy. A planned interim analysis showed
that capecitabine at a dose of 1000mgm
 2day
 1 had a better
toxicity profile than 5-FU: the rate of grade 3/4 diarrhoea,
stomatitis, or hand–foot syndrome was 5% in capecitabine-treated
patients compared with 17% in 5-FU-treated patients (Tebbutt
et al, 2004). In a second planned interim analysis of a higher
capecitabine dose of 1250mgm
 2day
 1, complete or partial
responses were seen in 31% of patients receiving epirubicin/
cisplatin/5-FU compared with 48% for those receiving epirubicin/
oxaliplatin/capecitabine (Sumpter et al, 2004). The rate of grade
3/4 fluoropyrimidine-related toxicity was 11% in capecitabine-
treated patients (1250mgm
 2day
 1) compared with 13% in
5-FU-treated patients.
In summary, XELOX combination chemotherapy is highly active
in patients with previously untreated advanced gastric cancer. This
novel combination regimen overcomes issues of poor tolerability
and inconvenience associated with other regimens currently used
in this cancer type. On the basis of these promising results, we
have initiated a large phase II multicentre study of XELOX in
advanced gastric cancer. A phase III adjuvant trial is also planned.
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